🔥 Gate Square Event: #PostToWinNIGHT 🔥
Post anything related to NIGHT to join!
Market outlook, project thoughts, research takeaways, user experience — all count.
📅 Event Duration: Dec 10 08:00 - Dec 21 16:00 UTC
📌 How to Participate
1️⃣ Post on Gate Square (text, analysis, opinions, or image posts are all valid)
2️⃣ Add the hashtag #PostToWinNIGHT or #发帖赢代币NIGHT
🏆 Rewards (Total: 1,000 NIGHT)
🥇 Top 1: 200 NIGHT
🥈 Top 4: 100 NIGHT each
🥉 Top 10: 40 NIGHT each
📄 Notes
Content must be original (no plagiarism or repetitive spam)
Winners must complete Gate Square identity verification
Gat
BioNTech rose about 8.5% after reaching a licensing protocol worth over $11 billion with Bristol-Myers Squibb.
Golden Ten Data reported on June 3 that BioNTech SE (BNTX.O) continued to rise about 8.5% to $122.7. The stock rose more than 18% yesterday. On the news side, Squibb announced that it has reached a licensing agreement with BioNTech for a new generation of anti-cancer drug BNT327, with milestone payments of up to $11.1 billion. Truist Securities raised its price target on BioNTech to $155 from $151, maintaining a “buy” rating.